Task Force on Sudden Cardiac Death of the European Society of Cardiology.

By S. Priori, E. Aliot, C. Blomström‐Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A. Camm, R. Cappato, S. Cobbe, C. D. Mario and 9 more. European Heart Journal, 2001

978 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Emergency Medicine

View Paper: https://www.semanticscholar.org/paper/36975abc4abb91b730cbdf5b6e0d4cd94766ccac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Peter Libby
2. P. Spirito
3. G. Hansson
4. S. Grundy
5. B. Maron
6. P. Ridker
7. C. Seidman
8. Rick A. Nishimura

In Emergency Medicine

1. Bernard R. Chaitman

Citations in the corpus

• Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. (2007, background): “Therefore, in high-risk long QT patients, especially cardiac arrest survivals, implantation of a cardioverter defibrillator should be recommended.(201,203)”
• From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. (2003, background): “The Task Force on Sudden Cardiac Death, organized by the European Society of Cardiology, issued a report that includes detailed diagnostic and therapeutic recommendations for a large number of cardiomyopathic conditions capable of causing sudden cardiac death [138].”
• ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. (2008, background): “Furthermore, electrophysiological testing is not useful in the management of patients with catecholaminergic polymorphic VT since the arrhythmia is usually not inducible with programmed ventricular stimulation (16,385,410,431).”
• From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. (2003, background): “The Task Force on Sudden Cardiac Death, organized by the European Society of Cardiology, issued a report that includes detailed diagnostic and therapeutic recommendations for a large number of cardiomyopathic conditions capable of causing sudden cardiac death [138].”
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G (2003, background): “Nevertheless, it is possible to identify most high-risk patients by noninvasive clinical markers (21,22,255), and only a small minority of those HCM patients who die suddenly (about 3%) are without any of the currently acknowledged risk markers (21).”
• ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, result): “This compares with the estimated SCD rate of 100 per 100 000 patient years in adult patients.(992) Given the low incidence of events, no randomized clinical trials have been performed to define either risk stratification for SCD in the young or the role of primary prevention therapies.”